SCHEMBL25274257

SCHEMBL25274257

FC(F)(F)Oc1n[nH]cc1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 2/20 0.43
▸ PTGDR2 Q9Y5Y4 2/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ BTK Q06187 1/20 0.34
▸ AKT1 P31749 1/20 0.34
▸ AKT2 P31751 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ SQOR Q9Y6N5 1/20 0.34
▸ SCN9A Q15858 2/20 0.34
▸ ADAMTS5 Q9UNA0 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ TRPA1 O75762 1/20 0.33
▸ PDE10A Q9Y233 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ CDC7 O00311 1/20 0.33
▸ PLK4 O00444 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6971232 0.80 AKT1 (0.39) METAP2L3MBTL1MAPTAKT1AKT2
SCHEMBL2576556 0.77 SCN10A (0.47) ALDH1A1
SCHEMBL1384959 0.77 SQOR (0.51) METAP2MAPTAKT1AKT2ALDH1A1
SCHEMBL1386288 0.76 NPC1 (0.35) MAPTAKT1AKT2ALDH1A1SQOR
SCHEMBL11633962 0.76 ENPP1 (0.42) METAP2PTGDR2L3MBTL1MAPTAKT1
SCHEMBL8632466 0.76 ENPP1 (0.42) METAP2PTGDR2L3MBTL1MAPTAKT1
SCHEMBL15202406 0.73 ALOX15 (0.41) METAP2L3MBTL1KDM4EMAPTAKT1
SCHEMBL10432295 0.73 ALDH1A1 (0.39) PTGDR2L3MBTL1KDM4EALDH1A1
SCHEMBL3263121 0.73 MAPK1 (0.43) L3MBTL1KDM4EMAPTALDH1A1SQOR
SCHEMBL1386673 0.71 SQOR (0.49) L3MBTL1KDM4EMAPTALDH1A1SQOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353851-A1 PURINES AND METHODS OF THEIR USE KINETA INC (US) 2025-11-20 — — US disclosed
CN-119031913-A Purine and methods of use thereof 奇尼塔公司 2024-11-26 — — CN disclosed
EP-4444312-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 — — EP disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353851-A1 PURINES AND METHODS OF THEIR USE TDP1, TDP2, PIKFYVE METAP2 2227/4885PTGDR2 4127/4885L3MBTL1 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback